• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.磁共振成像筛查在1型神经纤维瘤病儿童视路胶质瘤中的应用
J Pediatr. 2015 Oct;167(4):851-856.e1. doi: 10.1016/j.jpeds.2015.07.001. Epub 2015 Jul 29.
2
Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.1型神经纤维瘤病患者的视路胶质瘤:44例患者的随访
J AAPOS. 2010 Apr;14(2):155-8. doi: 10.1016/j.jaapos.2009.11.020.
3
Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.1型神经纤维瘤病中的视路胶质瘤:最新进展:监测、治疗指征及视力生物标志物
J Neuroophthalmol. 2017 Sep;37 Suppl 1(Suppl 1):S23-S32. doi: 10.1097/WNO.0000000000000550.
4
Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas.神经纤维瘤病 1 型和/或视神经胶质瘤患儿视力测试方法的可行性和比较。
Invest Ophthalmol Vis Sci. 2013 Feb 5;54(2):1034-8. doi: 10.1167/iovs.12-11385.
5
Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.视放射的各向异性分数与 1 型神经纤维瘤病视神经胶质瘤的视力丧失有关。
Neuro Oncol. 2013 Aug;15(8):1088-95. doi: 10.1093/neuonc/not068. Epub 2013 May 7.
6
The role of surgery in optic pathway/hypothalamic gliomas in children.手术在儿童视路/下丘脑胶质瘤中的作用。
J Neurosurg Pediatr. 2014 Jan;13(1):1-12. doi: 10.3171/2013.8.PEDS12546. Epub 2013 Oct 18.
7
Screening and diagnosis of optic pathway gliomas in children with neurofibromatosis type 1 by using sweep visual evoked potentials.使用扫描视觉诱发电位对1型神经纤维瘤病患儿的视路胶质瘤进行筛查和诊断。
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2895-902. doi: 10.1167/iovs.06-0429.
8
The Utility of Early Brain MRI for Patients with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Long-Term Follow-Up in a Tertiary Referral Hospital.神经纤维瘤病 1 型伴视神经胶质瘤患者早期脑部 MRI 的应用:在一家三级转诊医院的长期随访。
Neuropediatrics. 2022 Oct;53(5):370-375. doi: 10.1055/a-1816-8746. Epub 2022 Apr 5.
9
Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging.1型神经纤维瘤病合并视路胶质瘤患儿的视力丧失:磁共振成像显示与肿瘤位置的关系
Am J Ophthalmol. 2001 Apr;131(4):442-5. doi: 10.1016/s0002-9394(00)00852-7.
10
Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas.光学相干断层扫描在评估1型神经纤维瘤病合并视路胶质瘤患者中的应用
J AAPOS. 2010 Dec;14(6):511-7. doi: 10.1016/j.jaapos.2010.08.014.

引用本文的文献

1
Predictors in Optic Pathway Gliomas in Neurofibromatosis Type 1: A Single Center Study.1型神经纤维瘤病视路胶质瘤的预测因素:一项单中心研究
Cancers (Basel). 2025 Apr 23;17(9):1404. doi: 10.3390/cancers17091404.
2
Update on Pediatric Cancer Surveillance Recommendations for Patients with Neurofibromatosis Type 1, Noonan Syndrome, CBL Syndrome, Costello Syndrome, and Related RASopathies.神经纤维瘤病 1 型、努南综合征、CBL 综合征、科斯陶综合征及相关 RAS 通路疾病患者的儿科癌症监测推荐更新。
Clin Cancer Res. 2024 Nov 1;30(21):4834-4843. doi: 10.1158/1078-0432.CCR-24-1611.
3
Expanding the phenotype of neurofibromatosis type 1 microdeletion syndrome.扩展1型神经纤维瘤病微缺失综合征的表型。
Am J Med Genet C Semin Med Genet. 2024 Dec;196(4):e32095. doi: 10.1002/ajmg.c.32095. Epub 2024 Jul 18.
4
Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.1 型神经纤维瘤病患儿的黄斑神经节细胞层光学相干断层扫描在视神经胶质瘤评估中是一种有用的工具。
PLoS One. 2024 Jul 11;19(7):e0305548. doi: 10.1371/journal.pone.0305548. eCollection 2024.
5
An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic Strategies.神经纤维瘤病 1 型伴视神经通路胶质瘤概述:发病机制、危险因素和治疗策略。
Invest Ophthalmol Vis Sci. 2024 Jun 3;65(6):8. doi: 10.1167/iovs.65.6.8.
6
Optic Pathway Gliomas in Pediatric Population-Current Approach in Diagnosis and Management: Literature Review.儿童视神经通路胶质瘤——诊断与管理的当前方法:文献综述
J Clin Med. 2023 Oct 24;12(21):6709. doi: 10.3390/jcm12216709.
7
The Neuroimmune Regulation and Potential Therapeutic Strategies of Optic Pathway Glioma.视路胶质瘤的神经免疫调节及潜在治疗策略
Brain Sci. 2023 Oct 7;13(10):1424. doi: 10.3390/brainsci13101424.
8
Pediatric Optic Pathway Gliomas Resource Utilization and Prevalence in the OptumLabs Data Warehouse.小儿视神经胶质瘤在 OptumLabs 数据仓库中的资源利用和流行情况。
J Neuroophthalmol. 2024 Mar 1;44(1):10-15. doi: 10.1097/WNO.0000000000001960. Epub 2023 Jul 28.
9
Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects.1型神经纤维瘤病相关视路胶质瘤:当前挑战与未来前景
Cancer Manag Res. 2023 Jul 13;15:667-681. doi: 10.2147/CMAR.S362678. eCollection 2023.
10
Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B.在儿童脑肿瘤研究联盟(PBTC)-029B研究中,评估接受司美替尼治疗的1型神经纤维瘤病(NF1)儿童的信号强度局灶区域(FASI)。
Cancers (Basel). 2023 Mar 31;15(7):2109. doi: 10.3390/cancers15072109.

本文引用的文献

1
Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.性是导致 1 型神经纤维瘤病神经元功能障碍的主要因素。
Ann Neurol. 2014 Feb;75(2):309-16. doi: 10.1002/ana.24093. Epub 2014 Feb 6.
2
Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.1 型神经纤维瘤病相关视神经胶质瘤患儿化疗后的视觉预后:一项多中心回顾性分析。
Neuro Oncol. 2012 Jun;14(6):790-7. doi: 10.1093/neuonc/nos076. Epub 2012 Apr 3.
3
Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12.Arlm1 是一种位于小鼠染色体 12 上的星形细胞瘤抗性的雄性特异性修饰因子。
Neuro Oncol. 2012 Feb;14(2):160-74. doi: 10.1093/neuonc/nor206. Epub 2012 Jan 10.
4
A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.神经纤维瘤病 1 型(NF1)伴视神经胶质瘤患者的分子分析及基因型-表型相关性评估。
J Med Genet. 2011 Apr;48(4):256-60. doi: 10.1136/jmg.2010.081760. Epub 2011 Jan 28.
5
Utility of optic pathway glioma screening in young children with neurofibromatosis type I: questions generated by a clinical audit.神经纤维瘤病 1 型患儿视神经胶质瘤筛查的效用:临床审核引出的问题。
Eye (Lond). 2010 Oct;24(10):1603-5. doi: 10.1038/eye.2010.99. Epub 2010 Aug 6.
6
Natural history and management of low-grade glioma in NF-1 children.NF-1 患儿低级别胶质瘤的自然病史和治疗。
J Neurooncol. 2010 Nov;100(2):199-207. doi: 10.1007/s11060-010-0159-z. Epub 2010 Mar 30.
7
Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1.正电子发射断层扫描在 1 型神经纤维瘤病患儿肿瘤监测中的应用。
Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1309-17. doi: 10.1007/s00259-010-1386-4. Epub 2010 Feb 24.
8
Natural history and outcome of optic pathway gliomas in children.儿童视路胶质瘤的自然病史及预后
Pediatr Blood Cancer. 2009 Dec 15;53(7):1231-7. doi: 10.1002/pbc.22198.
9
Optic pathway gliomas: a review.视路胶质瘤:综述
Neurosurg Focus. 2007;23(5):E2. doi: 10.3171/FOC-07/11/E2.
10
Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.神经纤维瘤病1型中的视路胶质瘤:争议与建议
Ann Neurol. 2007 Mar;61(3):189-98. doi: 10.1002/ana.21107.

磁共振成像筛查在1型神经纤维瘤病儿童视路胶质瘤中的应用

The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.

作者信息

Prada Carlos E, Hufnagel Robert B, Hummel Trent R, Lovell Anne M, Hopkin Robert J, Saal Howard M, Schorry Elizabeth K

机构信息

Division of Human Genetics, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Cincinnati College of Medicine, Cincinnati, OH; Center for Genomic Medicine and Metabolism, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.

Division of Human Genetics, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Cincinnati College of Medicine, Cincinnati, OH.

出版信息

J Pediatr. 2015 Oct;167(4):851-856.e1. doi: 10.1016/j.jpeds.2015.07.001. Epub 2015 Jul 29.

DOI:10.1016/j.jpeds.2015.07.001
PMID:26233602
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9100836/
Abstract

OBJECTIVE

To evaluate the utility of screening brain/orbital magnetic resonance imaging (MRI) in a large population of children with neurofibromatosis type 1 (NF1) over a 20-year period.

STUDY DESIGN

A retrospective analysis of clinical and imaging data from children with NF1 seen at a single center between 1990 and 2010 was performed.

RESULTS

During the 20-year study period, 826 individuals with NF1 (402 females, 424 males) ages 1-9 years were screened for optic pathway gliomas (OPGs) using brain/orbital MRI; 18% were identified with OPGs with a median age at detection of 3 years. Fifteen percent of patients with OPGs had radiologic or clinical progression requiring therapy. Children with chiasmatic and postchiasmatic tumors were more likely to require therapy compared with patients with prechiasmatic OPGs (P < .0001). Patients with visual deficits at the time of diagnosis were more likely to experience visual decline despite therapy when compared with patients treated based on radiologic progression (P < .012).

CONCLUSIONS

Our findings confirm that chiasmatic and postchiasmatic OPG in children with NF1 have the highest risk for progression and vision loss. Early identification of OPG by screening MRI prior to the development of vision loss may lead to improved visual outcomes. Children with negative brain and orbital MRI screening at age 15 months or later did not develop symptomatic OPGs.

摘要

目的

评估在20年期间对大量1型神经纤维瘤病(NF1)儿童进行脑/眼眶磁共振成像(MRI)筛查的效用。

研究设计

对1990年至2010年在单一中心就诊的NF1儿童的临床和影像数据进行回顾性分析。

结果

在20年的研究期间,对826名年龄在1至9岁的NF1患者(402名女性,424名男性)进行了脑/眼眶MRI检查以筛查视神经通路胶质瘤(OPG);18%的患者被确诊患有OPG,确诊时的中位年龄为3岁。15%的OPG患者出现了需要治疗的影像学或临床进展。与视交叉前OPG患者相比,视交叉和视交叉后肿瘤的儿童更有可能需要治疗(P < .0001)。与基于影像学进展接受治疗的患者相比,诊断时存在视力缺陷的患者在接受治疗后更有可能出现视力下降(P < .012)。

结论

我们的研究结果证实,NF1儿童的视交叉和视交叉后OPG进展和视力丧失的风险最高。在视力丧失发生之前通过筛查MRI早期发现OPG可能会改善视力预后。15个月及以后脑和眼眶MRI筛查结果为阴性的儿童未出现有症状的OPG。